OIPE 13 2001 2

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperbork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 14498 TO (Modified)
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Shiret

Complete if Known				
Application Number:	09/899,780			
Filing Date:	July 5, 2001			
First Named Inventor:	Gary W. Wood			
Group Art Unit:	1642			
Examiner Name:	Not yet assigned - Alana M. Harris			
Attorney Docket Number.	70012590-04			

		OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
awn	,	David N. Liebowitz, M.D., Ph.D., and Carl H. June, M.D., "Recent Advances in Adoptive Immunotherap," <i>American Society of Clinical Oncology</i> , 1092-9118/99:302-312 (1999).	
		Gregory E. Plautz, M.D. et al., "Systemic T Cell Adoptive Immunotherapy of Malignant Gliomas," J Neurosurg., 89:42-51 (1998).	
		Alfred E. Chang and Suyu Shu, "Current Status of Adoptive Immunotherapy of Cancer," Crit. Rev. Oncol. Hem., 22:213-228 (1996).	
		Alfred E. Chang et al., "Adoptive Immunotherapy With Vaccine-Primed Lymph Node Cells Secondarily Activated With Anti-CD3 and Interleukin-2," J. of Clin. Oncol., 15:796-807 (1997).	
		Jan B. Vermorken et al., "Active Specific Immunotherapy for State II and State III Human Colon Cancer: a Randomised Trial," The Lancet, 353:345-350 (1999).	
		Alfred E. Change et al., *Clinical Observations on Adoptive Immunotherapy With Vaccine-Primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro,* Can. Res., 53:1043-1050 (1993).	
		Frank P. Holladay et al., "Autologous Tumor Cell Vaccination Combined With Adoptive Cellular Immunotherapy in Patients with Grade III/IV Astrocytoma," J. NeuroOncol., 27:179-189 (1996).	
		Stanley P. L. Leong et al., "Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) and Autologous Melanoma Vaccine Mediate Tumor Regression in Patients with Metastatic Melanoma," Journal of Immunotherapy, 22(2):166-174 (1999).	
		Gregory E. Plautz et al., "T-Cell Adoptive Immunotherapy of Metastatic Renal Cell Carcinoma," Urology, 54(4):617-624 (1999).	
	<u> </u>	Maurizio Bendandi et al., "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma," Nature Medicine, 5:1171-1177 (1999).	
\bigvee		Kruse and Beck, "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours," Biotechnol. Appl. Biochem, 25:197-205 (1997).	
			-

			·	
Examiner	ALIXALL:	Date	DAMMILAK 1	v 13. 2073
Signature	1 WUIT WYW	Considered	MMUNIC	(1)000
	N. T.		<i>V</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			Complete if Known			
Substitute for Form 1449A/PTO			Application Number:	09/899,780		
INFORMA"	TION DISC	LOSURE	Filing Date:	July 5, 2001		
STATEMENT BY APPLICANT			First Named Inventor:	Gary W. Wood		
•	any sheets as ne		Group Art Unit:	1642		
(650 65 116	, uncola do m	,00000.77	Examiner Name:	Not yot assigned Alana W. Harris, Phil		
1	of	2	Attorney Docket Number:	70012590-04		

Sheet

				U. S. PATENT DOCUMENTS		
Examiner Initials*	Cite No.1	U.S. Patent Docum	ment Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
60 W	5 426 422 Penent		Rosenberg	06-30-1992	rigules Appeal	
MA PUT	 	5,290,551		Berd	03-01-1994	
		5 140 000		Ochoa, et al.	08-22-1995	
DEC	3 2	715 404 500		Hanna, Jr., et al.	01-16-1996	
2 77	 	5,637,483		Dranoff, et al.	06-10-1997	
	<u> </u>	5,650,156		Grinstaff et al.	07-22-1997	
বিদ	ADEN	5,679,356		Bonnem, et al.	10-21-1997	
-17	11.	5,725,855		Ochoa, et al.	03-10-1998	
17		5,728,388		Terman	03-17-1998	
\land		5,766,920		Babbitt, et al.	06-16-1998	
	ļ					
	 					

FOREIGN PATENT DOCUMENTS								
	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	Γ
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T
			WO 97/05239		CELLTHERAPY, INC.	02-13-1997		
								↓_
					<u> </u>			1
								┼
								┼
								╄
			· · · · · · · · · · · · · · · · · · ·					╁
								+
								+-

Examiner	1000	Date 1,15/2079
Signature	WWWTAVVW	Considered 1/19/405
Olgitatare	T NO NA((* 10 0 000	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.